Cyberonics, Inc. (NASDAQ: CYBX), yesterday announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE